REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Type Diabetes Remission: Multidimensional Pharmacological Strategies and Future Perspectives
Provisionally accepted
- 1The First Hospital of Jilin University, Changchun, China
- 2Affiliated Hospital of Jilin Medical College, Jilin City, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Word count: 250 The high prevalence and severe complications of type 2 diabetes mellitus (T2DM) pose significant threats to public health systems worldwide. An in-depth understanding of T2DM pathophysiology has brought focused attention to pharmacological strategies for achieving disease remission. However, limited knowledge exists regarding their efficacy, patient stratification strategies, and long-term effects. By constructing an analytical framework integrating "mechanism-drug-strategies," we explore mechanisms of action and clinical effects of multiple medications (insulin, metformin, sodium–glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) for T2DM remission and analyze synergistic effects of combination therapies. Short-term intensive insulin therapy significantly improves β-cell function and insulin sensitivity, resulting in sustained glycemic remission in certain patients. Novel multi-target drugs (GLP-1/gastric inhibitory polypeptide dual agonists) demonstrate significant glycemic control and weight loss advantages. Non-antihyperglycemic drugs (vitamin D, sex hormones) demonstrate diabetes remission potential. Combined therapies (insulin with oral hypoglycemic agents, multitarget oral drug combinations) improve remission rates and prolong remission duration. This study systematically synthesized evidence on the multidimensional progress in pharmacological interventions for T2DM remission to support clinical practice and promote the transition of T2DM remission from a theoretical concept to individualized clinical application. Through an in-depth analysis of drug mechanisms of action and clinical research, new perspectives and strategies for optimizing treatment plans, improving diabetes remission rates, and reducing medication burdens, potentially providing important references for global T2DM management, are described. Future research focusing on long-acting combination strategies, predictive model construction, and translational medicine validation may cause a paradigm shift, from "glycemic control" to "disease remission."
Keywords: type 2 diabetes mellitus, Disease remission, Pharmacological interventions, glycemiccontrol, Combination strategies
Received: 21 Aug 2025; Accepted: 20 Nov 2025.
Copyright: © 2025 Liu, Gang, Liu, Jiang, Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guixia Wang, 7769288@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.